Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.
The companies formed the joint venture in 2008 to commercialize BioMérieux's IVD products and medical instruments in Japan.
The new company will develop microbiome diagnostics for multiple indications including inflammatory bowel disease and liver disorders.
Fulgent reached an agreement with two Chinese firms to establish a joint venture to offer genetic testing services in China.
The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.
Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Emory and Eurofins, following their JV last year, plan to open several clinical genetics labs across the globe that draw on EGL's expertise.
Horizon Discovery will use its experience with gene editing, immunology, and oncology to develop immunotherapies based on Centauri's antibody conjugate technology.
The JV will be based in London with operations in Cambridge, Massachusetts and will develop new treatments for blood disorders, blindness, and congenital heart disease.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.